Biopharmaceutical Industry Approaches to Facility Segregation for Viral Safety: An Effort from the Consortium on Adventitious Agent Contamination in Biomanufacturing.


Journal

PDA journal of pharmaceutical science and technology
ISSN: 1948-2124
Titre abrégé: PDA J Pharm Sci Technol
Pays: United States
ID NLM: 9439538

Informations de publication

Date de publication:
Historique:
pubmed: 27 10 2018
medline: 31 5 2019
entrez: 27 10 2018
Statut: ppublish

Résumé

Appropriate segregation within manufacturing facilities is required by regulators and utilized by manufacturers to ensure that the final product has not been contaminated with (a) adventitious viruses, (b) another pre-/postviral clearance fraction of the same product, or (c) another product processed in the same facility. However, there is no consensus on what constitutes appropriate facility segregation to minimize these risks. In part, this is due to the fact that a wide variety of manufacturing facilities and operational practices exist, including single-product and multiproduct manufacturing, using traditional segregation strategies with separate rooms for specific operations that may use stainless steel or disposable equipment to more modern ballroom-style operations that use mostly disposable equipment (i.e., pre- and postviral clearance manufacturing operations are

Identifiants

pubmed: 30361281
pii: pdajpst.2018.008862
doi: 10.5731/pdajpst.2018.008862
doi:

Substances chimiques

Biological Products 0
Recombinant Proteins 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

191-203

Informations de copyright

© PDA, Inc. 2019.

Auteurs

Paul W Barone (PW)

Center for Biomedical Innovation, Massachusetts Institute of Technology, Cambridge, MA, USA; pbarone@mit.edu.

Stephen Avgerinos (S)

Pfizer, Andover, MA, USA.

Rob Ballard (R)

Biogen, Durham, NC, USA.

Philip Clark (P)

Amgen, Thousand Oaks, CA, USA.

Chris Dowd (C)

Genentech, South San Francisco, CA, USA.

Lionel Gerentes (L)

Sanofi, France.

Ian Hart (I)

MedImmune, Gaithersburg, MD, USA.

Flora J Keumurian (FJ)

Center for Biomedical Innovation, Massachusetts Institute of Technology, Cambridge, MA, USA.

Johanna Kindermann (J)

Shire, Vienna, Austria.

James C Leung (JC)

Center for Biomedical Innovation, Massachusetts Institute of Technology, Cambridge, MA, USA.

Nguyen Ly (N)

Merck & Co., Inc., Kenilworth, NJ, USA.

Sheldon Mink (S)

Regeneron, Rensselaer, NY, USA.

Stefan Minning (S)

Boehringer Ingelheim, Germany.

Jürgen Mullberg (J)

Bristol-Myers Squibb, Devens, MA, USA.

Marie Murphy (M)

Eli Lilly, Dublin, Ireland.

Kerstin Nöske (K)

CSL Behring, Marburg, Germany; and.

Sandi Parriott (S)

BioMarin, San Rafael, CA, USA.

Bonnie Shum (B)

Amgen, Thousand Oaks, CA, USA.

Michael E Wiebe (ME)

Center for Biomedical Innovation, Massachusetts Institute of Technology, Cambridge, MA, USA.

Stacy L Springs (SL)

Center for Biomedical Innovation, Massachusetts Institute of Technology, Cambridge, MA, USA.

Articles similaires

Using Bayh-Dole Act March-In Rights to Lower US Drug Prices.

Lisa Larrimore Ouellette, Bhaven N Sampat
1.00
United States Cross-Sectional Studies Patents as Topic Humans Drugs, Generic
Humans Surgical Staplers Surgical Stapling Postoperative Complications Treatment Outcome
Animals Robotics Algorithms Sperm Whale Vocalization, Animal
Inclusion Bodies Solubility Recombinant Proteins Detergents Protein Denaturation

Classifications MeSH